Side Effects of TNF-α Blockers in Patients with Psoriatic Arthritis: Evidences from Literature Studies

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2013 Apr 17

PMID 23588881

Citations 7

Authors

Rosario Peluso

Giovanni Cafaro

Alessandro Di Minno

Salvatore Iervolino

Pasquale Ambrosino

Gelsy Lupoli

Matteo Nicola Dario Di Minno

Affiliations

Soon will be listed here.

Abstract

Psoriatic arthritis is an inflammatory rheumatic disorder, which occurs in patients with skin and/or nail psoriasis. In psoriatic arthritis, the importance of biologic mediators modulating inflammatory reaction, such as tumor necrosis factor, and the knowledge on their role in the pathogenesis of psoriatic arthritis influence the therapeutic choices. In the last years, the introduction of biologic drugs has greatly changed the treatment of psoriasis and psoriatic arthritis. In fact, tumor necrosis factor-α blockers demonstrated an effective action in the treatment of both skin and joint manifestations of psoriatic arthritis, but they have some adverse effects. The aim of this review is to revisit the literature data on adverse effects of tumor necrosis factor-α blockers in patients with psoriatic arthritis.

Citing Articles

Case Report: Paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy.

Cicogna G, Messina F, Nalotto L, Szekely S, Alaibac M F1000Res. 2019; 8:336.

PMID: 31448100 PMC: 6685451. DOI: 10.12688/f1000research.18493.1.

Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.

Kizhedath A, Wilkinson S, Glassey J Arch Toxicol. 2016; 91(4):1595-1612.

PMID: 27766364 PMC: 5364268. DOI: 10.1007/s00204-016-1876-7.

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.

Caso F, Costa L, Del Puente A, Di Minno M, Lupoli G, Scarpa R Ther Adv Chronic Dis. 2015; 6(6):328-38.

PMID: 26568809 PMC: 4622317. DOI: 10.1177/2040622315608647.

The impact of concomitant diffuse idiopathic skeletal hyperostosis on the achievement of minimal disease activity in subjects with psoriatic arthritis.

Pappone N, Di Minno M, Iervolino S, Lupoli R, Mader R, Zincarelli C Rheumatol Int. 2015; 35(12):2041-6.

PMID: 26048625 DOI: 10.1007/s00296-015-3303-4.

Management of arthropathy in inflammatory bowel diseases.

Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno M Ther Adv Chronic Dis. 2015; 6(2):65-77.

PMID: 25729557 PMC: 4331233. DOI: 10.1177/2040622314563929.

References

Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S . Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006; 33(12):2440-6. View

Esser A, Abril A, Fayne S, Doyle J . Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol. 2004; 50(5 Suppl):S75-7. DOI: 10.1016/j.jaad.2003.11.044. View

Tauber T, Turetz J, Barash J, Avni I, Morad Y . Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006; 10(1):26-9. DOI: 10.1016/j.jaapos.2005.12.002. View

Boehncke W, Boehncke S . Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012; 14(4):343-8. DOI: 10.1007/s11926-012-0260-8. View

OShea F, Marras T, Inman R . Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum. 2006; 55(6):978-81. DOI: 10.1002/art.22351. View

Sacquepee M, Rouleau V, Cantin J, Quirin N, Doussy Y, Valery J . [Active WHO class IV lupus nephritis in a patient treated with etanercept for a psoriasic arthritis]. Nephrol Ther. 2010; 6(6):537-40. DOI: 10.1016/j.nephro.2010.05.003. View

Gifre L, Ruiz-Esquide V, Xaubet A, Gomez-Puerta J, Hernandez M, Sanmarti R . Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol. 2010; 47(4):208-12. DOI: 10.1016/j.arbres.2010.05.011. View

Coppack S . Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001; 60(3):349-56. DOI: 10.1079/pns2001110. View

Berthelot J, De Bandt M, Goupille P, Solau-Gervais E, Liote F, Goeb V . Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine. 2008; 76(1):28-34. DOI: 10.1016/j.jbspin.2008.04.016. View

10.

Louie G, Chitkara P, Ward M . Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis. 2008; 67(6):896-8. PMC: 11057365. DOI: 10.1136/ard.2007.078840. View

11.

Panitch H, Hirsch R, Haley A, Johnson K . Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1987; 1(8538):893-5. DOI: 10.1016/s0140-6736(87)92863-7. View

12.

Mease P, Goffe B . Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol. 2005; 52(1):1-19. DOI: 10.1016/j.jaad.2004.06.013. View

13.

Santos-Juanes J, Coto-Segura P, Mallo S, Galache C, Soto J . Multiple eruptive dermatofibromas in a patient receiving efalizumab. Dermatology. 2008; 216(4):363. DOI: 10.1159/000117708. View

14.

Selmaj K, Raine C . Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 1988; 23(4):339-46. DOI: 10.1002/ana.410230405. View

15.

Mounach A, Rezqi A, Nouijai A, Ghozlani I, Achemlal L, El Maghraoui A . Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int. 2011; 33(5):1351-3. DOI: 10.1007/s00296-011-2212-4. View

16.

Cope A, Ettinger R, McDevitt H . The role of TNF alpha and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol. 1997; 148(5):307-12. DOI: 10.1016/s0923-2494(97)87239-2. View

17.

Kwon H, Cote T, Cuffe M, Kramer J, Braun M . Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003; 138(10):807-11. DOI: 10.7326/0003-4819-138-10-200305200-00008. View

18.

Di Minno M, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R . Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost. 2012; 38(5):497-505. DOI: 10.1055/s-0032-1306433. View

19.

Antoniou C, Kosmadaki M, Stratigos A, Katsambas A . Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology. 2008; 216(4):364-5. DOI: 10.1159/000117709. View

20.

Di Minno M, Iervolino S, Peluso R, Scarpa R, Di Minno G . Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011; 31(3):705-12. DOI: 10.1161/ATVBAHA.110.214585. View